Drug intelligence / Profile preview

TJ097

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Small Molecules

Overview

TJ097 is a preclinical-stage small molecule therapeutic being developed by Tuojie Biotech for the treatment of solid tumors. As a preclinical candidate (PCC), the compound is currently undergoing evaluation to determine its safety and efficacy profiles prior to potential clinical trial initiation. While specific molecular targets for TJ097 have not been publicly disclosed in the company's high-level pipeline summaries, it is part of Tuojie Biotech's oncology portfolio, which focuses on innovative small molecule inhibitors targeting key pathways in cancer biology.

Beyond the preview

Go deeper on TJ097.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ097.

Explore the full profile